Caicun Zhou
Tongji University · 67 works · 1,091 citations · h-index 16
Top works
- Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
- E-Cigarettes and Cancer Patients
- EGFR‐targeted therapy alters the tumor microenvironment in EGFR‐driven lung tumors: Implications for combination therapies
- Targeting BRAF mutations in non-small cell lung cancer
- OA09.06 IMpower151: Phase III Study of Atezolizumab + Bevacizumab + Chemotherapy in 1L Metastatic Nonsquamous NSCLC
- Prognostic value of PD ‐L1 expression in combination with CD 8 + TIL s density in patients with surgically resected non‐small cell lung cancer
- A Multicenter, Open-Label, Randomized Phase II Controlled Study of rh-Endostatin (Endostar) in Combination with Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer
- Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
- Progress and challenges of artificial intelligence in lung cancer clinical translation
- [Impact of erlotinib treatment on symptoms and quality of life in patients with advanced non-small-cell lung cancer].
- Tumour microenvironment changes after osimertinib treatment resistance in non-small cell lung cancer
- [Clinical characteristics and diagnosis of pulmonary mucosa-associated lymphoid tissue-derived (MALT) lymphoma: a retrospective analysis of 29 cases].
- Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations
- Transcutaneous electrical acupoint stimulation (TEAS) ameliorates chemotherapy-induced bone marrow suppression in lung cancer patients
- Challenges and countermeasures of thoracic oncology in the epidemic of COVID-19
- SPOP promotes FADD degradation and inhibits NF-κB activity in non-small cell lung cancer
- MA11.02 KEYNOTE-042 China Study: First-Line Pembrolizumab vs Chemotherapy in Chinese Patients with Advanced NSCLC with PD-L1 TPS ≥1%
- Cerebrospinal fluid-derived circulating tumor DNA is more comprehensive than plasma in NSCLC patients with leptomeningeal metastases regardless of extracranial evolution
- Iconographies supplémentaires de l'article : Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- EGFR amplification is a putative resistance mechanism for NSCLC–LM patients with TKI therapy and is associated with poor outcome